Latest Breaking News On - University of washington department medicine - Page 1 : comparemela.com

The cost of obesity: How much can patients save by losing weight?

Q&A: Obesity Medicine 2024 is 'a pinnacle moment,' featuring latest updates in treatment

Seagen Inc. - TUKYSA in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

BOTHELL - Seagen Inc. today announced data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA in combination with the antibody-drug conjugate ado-trastuzumab emtansine . The combination showed.

HER2+ Combo Shows Promise in Breast Cancer Brain Mets

In previously treated patients with locally advanced unresectable or metastatic HER2-positive breast cancer, tucatinib and trastuzumab emtansine improved progression-free survival vs T-DM1 alone.

Tucatinib, Trastuzumab Combination Improves Progression-Free Survival in HER2+, Locally Advanced or Metastatic Breast Cancer

Improvements in PFS were also seen among patients with brain metastases.